Novel Screening Modality for Early Gastric Cancer

2019-10-09 09:21:39 | BioPortfolio


Potential patients will be recruited at participating sites based on routine care with clinical indications for upper endoscopy. After careful review of their inclusion and exclusion criteria, patients will be approached regarding the study and if interested, they will be consented and usual standard of care procedures performed. Patients will undergo their scheduled endoscopy with standard forceps biopsies along with WATS brush samples. Documentation of the consent process and procedure will be done as well as data collection related to this study. All samples including standard of care samples and WATS samples will be sent for histologic analysis.

Study Design


Gastric Cancer


Hospital de Occidente
Santa Rosa De Copán


Not yet recruiting


University of Alabama at Birmingham

Results (where available)

View Results


Published on BioPortfolio: 2019-10-09T09:21:39-0400

Clinical Trials [1335 Associated Clinical Trials listed on BioPortfolio]

Proteiomic Fingerprints of Gastric Juice

No accurate, inexpensive and non-invasive test for gastric cancer screening is currently available. The investigators' recent study identified a1-antitrypsin and other proteins as potentia...

Early Onset and Familial Gastric Cancer Registry

The purpose of this study is to establish a gastric cancer registry. A registry is a database of information. With the registry, we can learn more about the genetic causes of gastric cance...

Gastric Cancer Surgery in Elderly Patients

Gastric cancer is most frequent after the fifth decade of life. Surgical risk is higher in aged population because of general health condition may affect the postoperative result. Aim of t...

Study of TS-1 or TS-1 + PSK for Gastric Cancer Patients

Since it is not uncertain about efficacy of combination therapy with PSK and TS-1 in gastric cancer, in this study, we compare efficacy and safety of postoperative adjuvant therapy using T...

Next-generation Sequencing in Gastric Cancer to Evaluation Prognosis

Liquid biopsy has been widely used in the diagnosis and treatment of tumors, and cfDNA has always been a hot spot in clinical research. Previous studies have shown that cfDNA may be associ...

PubMed Articles [14242 Associated PubMed Articles listed on BioPortfolio]

LBX2-AS1/miR-219a-2-3p/FUS/LBX2 positive feedback loop contributes to the proliferation of gastric cancer.

Long non-coding RNAs (lncRNAs) are increasingly investigated in numerous carcinomas containing gastric cancer (GC). The aim of our research is to inquire about the expression profile and role of LBX2-...

Comment on: "Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features. Gastric Cancer, 2019: 1-10" by Wang et al.

Nervous system and gastric cancer.

The nervous system has been recently shown to exert impact on gastric cancer directly and indirectly. Gastric cancer cells invade nerve fibers to induce outgrowth and branching of neural cells, and ne...

Correction to: KRAS status is related to histological phenotype in gastric cancer: results from a large multicentre study.

In the original publication of this article, Fig. 2 was published incorrectly. The correct Fig. 2 is given in this correction.

MiR-99a suppresses cell migration and invasion by regulating IGF1R in gastric cancer.

Gastric cancer is a common kind of gastrointestinal malignancies. Increasing evidence indicates dysregulation of microRNA-99a (miR-99a) in gastric cancer, and has been extensively investigated in term...

Medical and Biotech [MESH] Definitions

That portion of the stomach remaining after gastric surgery, usually gastrectomy or gastroenterostomy for cancer of the stomach or peptic ulcer. It is a common site of cancer referred to as stump cancer or carcinoma of the gastric stump.

A proto-oncogene protein and member of the Wnt family of proteins. It is frequently up-regulated in human GASTRIC CANCER and is a tumor marker (TUMOR MARKERS, BIOLOGICAL) of gastric and COLORECTAL CANCER.

A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.

Abnormal distention of the STOMACH due to accumulation of gastric contents that may reach 10 to 15 liters. Gastric dilatation may be the result of GASTRIC OUTLET OBSTRUCTION; ILEUS; GASTROPARESIS; or denervation.

Vagal denervation of that part of the STOMACH lined with acid-secreting mucosa (GASTRIC MUCOSA) containing the GASTRIC PARIETAL CELLS. Since the procedure leaves the vagal branches to the antrum and PYLORUS intact, it circumvents gastric drainage required with truncal vagotomy techniques.

More From BioPortfolio on "Novel Screening Modality for Early Gastric Cancer"

Quick Search

Searches Linking to this Trial